Restructuring for Success: Shifting Biotech Strategies

During a panel discussion at Elsevier Business Intelligence’s Therapeutic Area Partnerships conference in Boston in December 2011, experienced investors and biotech executives drew lessons from difficult restructurings and successful transitions.

At a January 2012 Goldman Sachs CEO conference, Merck & Co. Inc. CEO Ken Frazier, noting his company’s poor investor return in 2011 relative to its peers, acknowledged the company’s shortcomings for the year. But then he implored his investor audience that while they were free and right to judge Merck on its successes and failures, they should also judge the company on how it responded – clinically, strategically, structurally – in the face of ill fortune. “The company showed a significant amount of adaptability and resilience in the face of that … and it was a positive year in terms of what got done,” said Frazier.

His is an argument that isn’t just the defensive posturing of a large company executive. In biotech, where failure and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo